Sagimet Biosciences reports preliminary cash of $94.9M as of Dec 31, 2023

Sagimet Biosciences Inc.

Cash, cash equivalents and short-term investments estimated at ~$94.9M.
Amount is unaudited, prepared by management and subject to completion of closing procedures.
Actual year-end 2023 results may differ; will be included in Form 10-K.

item 2.02 item 9.01

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-006042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.